Literature DB >> 12364985

KTP laser ablation of Barrett's esophagus after anti-reflux surgery results in long-term loss of intestinal metaplasia. Potassium-titanyl-phosphate.

S P Bowers1, S G Mattar, P J Waring, K Galloway, A Nasir, R Pascal, J G Hunter, S G Mattear.   

Abstract

BACKGROUND: Efforts to ablate Barrett's epithelium have met with mixed results. We report the long-term follow-up evaluation of the preliminary cohort of patients who underwent thermal ablation of Barrett's epithelium with the potassium-titanyl-phosphate (KTP) laser after anti-reflux surgery.
METHODS: Nine patients with intestinal metaplasia (IM) of the esophagus underwent fundoplication (7 laparoscopic Nissen, 1 laparoscopic Toupet, 1 open Nissen) between May 1993 and October 1994. Three patients had an IM less than 3 cm long (33%). One year after the operation, all the patients were symptom free, had discontinued medications, and had a normal 24-h pH study. From June 1995 to February 1996, these patients underwent a median of two (range, 1-5) endoscopic procedures with directed mucosal ablation using the KTP laser. A comparative cohort of 21 patients (IM length, <3cm; 38%) treated during the same period with fundoplication alone served as a control. The patients were followed prospectively with annual or biennial endoscopy and biopsy. All the patients were contacted by mail, telephone, or clinic visit annually to determine symptomatic and quality-of-life outcome of antireflux surgery.
RESULTS: The mean follow-up period was 6.8 years (range, 6-7.5 years). At this writing, the study patients are alive and well. Eight of the patients have experienced histologic loss of IM (89%) according to their last biopsy result. One patient has had regression of low-grade dysplasia to IM. The patients treated with fundoplication alone had a mean follow-up period of 5.6 years (range, 4.7-7.2 years). On the basis of the last biopsy result, 7 of 21 patients (33%) had no evidence of IM.
CONCLUSIONS: A program of tailored antireflux surgery followed by thermal mucosal ablation causes a loss of IM in a majority of patients with Barrett's esophagus. This may represent a significant improvement in histologic outcome over that of treatment with fundoplication alone (p = 0.007 Fisher's exact test).

Entities:  

Mesh:

Year:  2002        PMID: 12364985     DOI: 10.1007/s00464-001-8155-1

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  6 in total

Review 1.  Barrett's esophagus--Who, how, how often and what to do with dysplasia?

Authors:  Lawrence C Hookey
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

2.  Long-term results of ablation with antireflux surgery for Barrett's esophagus: a clinical and molecular biologic study.

Authors:  Tuuli Kauttu; Jari Räsänen; Leena Krogerus; Eero Sihvo; Pauli Puolakkainen; Jarmo A Salo
Journal:  Surg Endosc       Date:  2012-01-05       Impact factor: 4.584

Review 3.  Risk of recurrence of Barrett's esophagus after successful endoscopic therapy.

Authors:  Rajesh Krishnamoorthi; Siddharth Singh; Karthik Ragunathan; David A Katzka; Kenneth K Wang; Prasad G Iyer
Journal:  Gastrointest Endosc       Date:  2016-02-20       Impact factor: 9.427

4.  Initial experience with new intraluminal devices for GERD, Barrett's esophagus, and obesity.

Authors:  Charles J Filipi; Rudolf J Stadlhuber
Journal:  J Gastrointest Surg       Date:  2009-09-24       Impact factor: 3.452

Review 5.  Treatment for Barrett's oesophagus.

Authors:  Jonathan Re Rees; Pierre Lao-Sirieix; Angela Wong; Rebecca C Fitzgerald
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 6.  Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy.

Authors:  Devidas Menon; Tania Stafinski; Heng Wu; Darren Lau; Clarence Wong
Journal:  BMC Gastroenterol       Date:  2010-09-27       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.